Wysoczynski et al. proposed that leukemia inhibitory factor (LIF) promotes the progression and the metastatic behavior of rhabdomyosarcoma cells, contributing to the resistance of rhabdomyosarcoma to conventional treatment [46]. The gene discussed is LIF; the disease is rhabdomyosarcoma.